Johnson & Johnson (JNJ)

Currency in USD
174.42
+1.64(+0.95%)
Closed·
174.53+0.11(+0.06%)
·
JNJ Scorecard
Full Analysis
Has raised its dividend for 54 consecutive years
JNJ is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
172.70174.54
52 wk Range
140.68174.76
Key Statistics
Prev. Close
174.42
Open
173
Day's Range
172.7-174.54
52 wk Range
140.68-174.76
Volume
5.88M
Average Volume (3m)
8.38M
1-Year Change
10.12%
Book Value / Share
32.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
JNJ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
174.92
Upside
+0.29%
Members' Sentiments
Bearish
Bullish
ProTips
16 analysts have revised their earnings upwards for the upcoming period

Johnson & Johnson News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Employees
138100

Johnson & Johnson SWOT Analysis


Oncology Powerhouse
Johnson & Johnson's oncology division emerges as a key growth driver, with CARVYKTI leading the charge and projections of $50 billion in oncology sales by 2030
Financial Resilience
Despite challenges, J&J reports robust Q4 2024 results with 5.9% adjusted operational sales growth, surpassing expectations and demonstrating financial stability
Strategic Expansion
J&J explores CAR-T therapies beyond oncology, venturing into autoimmune diseases and strengthening its portfolio through strategic acquisitions like V-Wave
Analyst Perspectives
Price targets range from $152 to $215, reflecting varied outlooks on J&J's growth potential amid ongoing talc litigation and upcoming Stelara biosimilar competition
Read full SWOT analysis

Johnson & Johnson Earnings Call Summary for Q1/2025

  • J&J beats Q1 2025 estimates: EPS $2.77 vs $2.58 forecast, revenue $21.9B vs $21.57B expected. Stock dips 0.39% pre-market despite strong results.
  • Revenue up 4.2% YoY to $21.9B. U.S. sales grow 5.9%, international sales up 2.1%. Key products DARZALEX and TREMFYA show significant growth.
  • Full-year operational sales growth projected at 3.3-4.3%. Stronger growth expected in H2 2025 due to pipeline advancements and approvals.
  • CEO highlights 2025 as pivotal for accelerated growth. Company plans substantial U.S. investments and new manufacturing facilities.
  • Risks include Stelara biosimilar competition, global economic uncertainties, regulatory hurdles, and potential supply chain disruptions.
Last Updated: 15/04/2025, 14:52
Read Full Transcript

Compare JNJ to Peers and Sector

Metrics to compare
JNJ
Peers
Sector
Relationship
P/E Ratio
18.5x18.8x−0.5x
PEG Ratio
−0.460.130.00
Price/Book
5.4x1.4x2.6x
Price / LTM Sales
4.6x2.2x3.3x
Upside (Analyst Target)
1.3%0.0%40.3%
Fair Value Upside
Unlock32.2%4.7%Unlock

Analyst Ratings

10 Buy
14 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 174.92
(+0.29% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 9.42%
Dividend Yield
2.98%
Industry Median 2.94%
Annualised payout
5.20
Paid quarterly
5-Years Growth
+5.40%
Growth Streak

Earnings

Latest Release
Jul 16, 2025
EPS / Forecast
2.77 / 2.68
Revenue / Forecast
23.74B / 22.86B
EPS Revisions
Last 90 days

JNJ Income Statement

People Also Watch

271.81
UNH
+3.91%
70.63
PYPL
+3.91%
351.07
ADBE
+3.73%
107.60
XOM
+1.39%
289.33
AMGN
+1.53%

FAQ

What Stock Exchange Does J&J Trade On?

J&J is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for J&J?

The stock symbol for J&J is "JNJ."

What Is the J&J Market Cap?

As of today, J&J market cap is 420.06B.

What Is J&J's Earnings Per Share (TTM)?

The J&J EPS (TTM) is 9.42.

When Is the Next J&J Earnings Date?

J&J will release its next earnings report on 20 Oct 2025.

From a Technical Analysis Perspective, Is JNJ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has J&J Stock Split?

J&J has split 6 times.

How Many Employees Does J&J Have?

J&J has 138100 employees.

What is the current trading status of J&J (JNJ)?

As of 14 Aug 2025, J&J (JNJ) is trading at a price of 174.42, with a previous close of 174.42. The stock has fluctuated within a day range of 172.70 to 174.54, while its 52-week range spans from 140.68 to 174.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.